Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208842 | 0.83 | CYP1A2 (0.38) | CYP1A2CYP2A6GFERAXLALDH1A1 | |
| SCHEMBL7246322 | 0.74 | ESR1 (0.41) | CYP1A2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL207540 | 0.74 | CYP2A6 (0.38) | CYP2A6GFERALDH1A1MAPTLMNA | |
| SCHEMBL151104 | 0.74 | CYP2A6 (0.38) | CYP1A2CYP2A6ALDH1A1MAPTKDM4E | |
| SCHEMBL147443 | 0.74 | EPHX2 (0.42) | GFERALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL533978 | 0.74 | TRPV4 (0.30) | — | |
| SCHEMBL169044 | 0.73 | — | — | |
| SCHEMBL533084 | 0.73 | — | — | |
| SCHEMBL20895124 | 0.72 | PGR (0.38) | ALDH1A1AHRRAB9AAPP | |
| SCHEMBL5534967 | 0.71 | EPHX2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11878981-B2 | Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-01-23 | — | — | US | claimed |
| CN-110023309-B | Indazole derivatives as glucagon receptor antagonists | 詹森药业有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | US | claimed |
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-15 | — | — | US | claimed |
| EP-3510026-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-12 | — | — | EP | claimed |
| EP-3510028-B1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | claimed |
| EP-3510022-B1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | claimed |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-18 | — | — | US | claimed |
| EP-3510026-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | claimed |
| EP-3510028-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| CN-1582287-A | Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | CN | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-30 | — | — | US | claimed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1423386-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-02 | — | — | EP | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | claimed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774048-B2 | Indazole derivatives useful as glucagon receptor antagonists | GPR119, GLP1R, GIPR | CYP1A2 296/4885CYP2A6 917/4885GFER 1984/4885 |
| US-20200377462-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP1A2 296/4885CYP2A6 917/4885GFER 1984/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | CYP1A2 2631/4885CYP2A6 2751/4885GFER 1138/4885 |
| US-20040266826-A1 | Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors | TNF, MMP9, MMP1 | CYP1A2 1151/4885CYP2A6 1458/4885GFER 2826/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | CYP1A2 2631/4885CYP2A6 2751/4885GFER 1138/4885 |
| US-11878981-B2 | Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors | TRPA1, TRPV1, TRPV3 | CYP1A2 2352/4885CYP2A6 3019/4885GFER 2053/4885 |
| US-20190218186-A1 | INDAZOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GLP1R, GIPR | CYP1A2 296/4885CYP2A6 917/4885GFER 1984/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | CYP1A2 273/4885CYP2A6 1405/4885GFER 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.